Head-To-Head Comparison: Valeritas (VLRX) and Prourocare Medical (PUMD)

Valeritas (NASDAQ:VLRX) and Prourocare Medical (OTCMKTS:PUMD) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, institutional ownership, profitability, earnings, dividends, risk and analyst recommendations.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Valeritas and Prourocare Medical, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Valeritas 0 0 3 0 3.00
Prourocare Medical 0 0 0 0 N/A

Valeritas currently has a consensus target price of $2.17, indicating a potential upside of 647.13%. Given Valeritas’ higher probable upside, analysts clearly believe Valeritas is more favorable than Prourocare Medical.

Earnings and Valuation

This table compares Valeritas and Prourocare Medical’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Valeritas $26.40 million 1.17 -$45.93 million ($1.71) -0.17
Prourocare Medical N/A N/A N/A N/A N/A

Prourocare Medical has lower revenue, but higher earnings than Valeritas.

Profitability

This table compares Valeritas and Prourocare Medical’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Valeritas -183.53% -1,757.04% -87.00%
Prourocare Medical N/A N/A N/A

Institutional & Insider Ownership

35.5% of Valeritas shares are held by institutional investors. 1.0% of Valeritas shares are held by insiders. Comparatively, 29.3% of Prourocare Medical shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Volatility & Risk

Valeritas has a beta of 2, indicating that its share price is 100% more volatile than the S&P 500. Comparatively, Prourocare Medical has a beta of 7.28, indicating that its share price is 628% more volatile than the S&P 500.

Summary

Prourocare Medical beats Valeritas on 5 of the 9 factors compared between the two stocks.

About Valeritas

Valeritas Holdings, Inc., a commercial-stage medical technology company, focuses on the development and commercialization of technologies to treat patients with Type 2 diabetes in the United States. The company offers V-Go, a wearable insulin delivery device for basal-bolus therapy. It also develops V-Go Prefill that is in the design-development stage for eliminating the device-filling process and the need for EZ fill refrigeration for patients with Type 2 diabetes; and V-Go SIM for real-time tracking information of basal and bolus dosing utilization. The company sells V-Go to third-party wholesalers and medical supply distributors. Valeritas Holdings, Inc. was founded in 2006 and is headquartered in Bridgewater, New Jersey.

About Prourocare Medical

ProUroCare Medical Inc. engages in developing products for the detection and characterization of male urological prostate disease. It offers the ProUroScan System, a prostate imaging system that aids the physician in documenting abnormalities in the prostate that have been previously detected by a digital rectal exam. The company has licensing, development, and commercialization agreements with Artann Laboratories Inc. for its ProUroScan System. ProUroCare Medical Inc. was founded in 1999 and is based in Eden Prairie, Minnesota.

Receive News & Ratings for Valeritas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeritas and related companies with MarketBeat.com's FREE daily email newsletter.